Drug intelligence / Profile preview

EGEN-RNA-002

Development stage: Preclinical
Lead developer: IMUNON
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intraperitoneal

Overview

EGEN-RNA-002 is a small interfering RNA (siRNA) therapeutic developed through a collaboration between SurModics and EGen. It leverages EGen's proprietary TheraSilence technology platform and SurModics' expertise in drug delivery to create long-term delivery systems for siRNA. The drug is designed to silence specific gene expression, aiming to treat diseases such as cancer and genetic disorders. The sustained-release mechanism is intended to improve safety, efficacy, and patient convenience.

Beyond the preview

Go deeper on EGEN-RNA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGEN-RNA-002.

Explore the full profile